| Literature DB >> 25882048 |
M Itsumi1, S Inoue1, A J Elia1, K Murakami1, M Sasaki1, E F Lind1, D Brenner1,2, I S Harris1, I I C Chio1, S Afzal1,3, R A Cairns1, D W Cescon1, A R Elford1, J Ye1, P A Lang1,4,5, W Y Li1, A Wakeham1, G S Duncan1, J Haight1, A You-Ten1, B Snow1, K Yamamoto1, P S Ohashi1,3, T W Mak1,3.
Abstract
Isocitrate dehydrogenase-1 (Idh1) is an important metabolic enzyme that produces NADPH by converting isocitrate to α-ketoglutarate. Idh1 is known to reduce reactive oxygen species (ROS) induced in cells by treatment with lipopolysaccharide (LPS) in vitro. Here, we used Idh1-deficient knockout (Idh1 KO) mice to investigate the role of Idh1 in antioxidant defense in vivo. Idh1 KO mice showed heightened susceptibility to death induced by LPS and exhibited increased serum levels of inflammatory cytokines such as tumor necrosis factor-α and interleukin-6. The serum of LPS-injected Idh1 KO mice also contained elevated levels of AST, a marker of inflammatory liver damage. Furthermore, after LPS injection, livers of Idh1 KO mice showed histological evidence of elevated oxidative DNA damage compared with livers of wild-type (WT) mice. Idh1 KO livers showed a faster and more pronounced oxidative stress than WT livers. In line with that, Idh1 KO hepatocytes showed higher ROS levels and an increase in the NADP(+)/NADPH ratio when compared with hepatocytes isolated from WT mice. These results suggest that Idh1 has a physiological function in protecting cells from oxidative stress by regulating the intracellular NADP(+)/NADPH ratio. Our findings suggest that stimulation of Idh1 activity may be an effective therapeutic strategy for reducing oxidative stress during inflammatory responses, including the early stages of septic shock.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25882048 PMCID: PMC4648331 DOI: 10.1038/cdd.2015.38
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 15.828
Figure 1Confirmation of Idh1 deletion in Idh1 LSL/LSL (Idh1 KO) mice. Immunoblot analysis to detect Idh1, Idh2 and Idh3 proteins in extracts of brain, liver and spleen from WT Idh1 wt/wt (W), heterozygous Idh1 wt/LSL (H) and Idh1 LSL/LSL Idh1 KO (K) mice. Actin, loading control. Results are representative of three mice per group
Figure 2Increased in vivo susceptibility of Idh1 KO mice to LPS-induced septic shock. (a) Kaplan–Meier analysis of the survival of Idh1 KO and WT mice (n=22 per group) that received a sublethal dose of LPS (50 μg) and were monitored for 5 days. Data are expressed as percent survival. ***P<0.001. (b) Quantitation by ELISA of serum levels of the indicated cytokines in the mice in (a) at 2 h after LPS injection. Data are expressed as the fold change relative to values in LPS-treated WT mice and are the mean±S.D. (n=22). **P<0.01 and ***P<0.001
Figure 3Idh1 in non-hematopoietic cells protects against LPS-induced septic shock. Kaplan–Meier analysis of the survival of lethally irradiated WT mice (n=11) that had been reconstituted with Idh1 KO BM cells (KO>WT, ●), as well as lethally irradiated Idh1 KO mice (n=10) that had been reconstituted with WT BM cells (WT>KO, ▪). Mice received a sublethal LPS dose at 10 weeks after reconstitution and survival was monitored for 7 days. Data are expressed as percent survival. **P<0.01
Figure 4Loss of Idh1 exacerbates LPS-induced liver injury. (a) Quantitation of serum levels of (top) AST and (bottom) ALT in Idh1 KO and WT mice that received a sublethal LPS dose. Blood samples were collected at 6 h after LPS injection. Data are expressed as the fold change relative to values in LPS-treated WT mice and are the mean±S.D. (n=6). *P<0.05. (b) TUNEL staining of apoptotic cells in the livers of the mice in (a), which were killed at 12 h after LPS injection. Top: TUNEL staining; bottom: DAPI (4',6-diamidino-2-phenylindole). Magnification × 10. Quantitation of apoptotic cells in the livers was shown on the right. Data were collected as described in Materials and Methods and are the mean percentage of TUNEL+ cells±S.D. *P<0.05
Figure 5Loss of Idh1 induces excessive ROS accumulation in the liver. (a) Histological staining to detect the oxidative stress marker 8-OHdG (brown) in livers of Idh1 KO and WT mice that received sublethal LPS injection and were killed 6 h or 12 h later, as indicated. Results presented are representative of two sections per mouse in two mice per group at 6 h and the average of five sections per mouse in six mice per group at 12 h. Scale bars, 1 mm (6 h), 0.5 mm (12 h) and 50 μm (insets). (b and c) Quantitative PCR analysis of mRNA levels of the indicated ROS-inducing (b) and antioxidant (c) genes in livers of Idh1 KO and WT mice that received a sublethal LPS dose. Liver extracts were prepared at 6 h after LPS injection. Data are expressed as the fold change relative to values in LPS-treated WT mice and are the mean±S.D. (n=3). *P<0.05
Figure 6Idh1 KO hepatocytes accumulate ROS even at steady state. (a) Flow cytometric determination of ROS levels in steady-state WT and Idh1 KO hepatocytes that were stained with DCFDA. Data are representative of three cultures per group and three experiments. (b) Quantitation of the intracellular NADP+/NADPH ratio in steady-state hepatocytes (left) and sublethal LPS-injected hepatocytes at 6 h (right) of each WT and Idh1 KO mice determined as described in Materials and Methods. *P<0.05 and ***P<0.001. (c) Quantitative PCR analysis of mRNA levels of the indicated ROS-related genes in steady-state WT and Idh1 KO hepatocytes. Data are expressed as the fold change relative to values in WT hepatocytes and are the mean±S.D. (n=3). *P<0.05; **P<0.01; ***P<0.001
Figure 7NAC-treated Idh1 KO mice increase survival. Kaplan–Meier analysis of the survival of LPS-injected Idh1 KO mice and WT mice treated with (n=6 for each genotype) or without (n=8 for each genotype) NAC included in drinking water. These mice received a sublethal dose of LPS (50 μg) and were monitored for 5 days. Data are expressed as percent survival. **P<0.01